Review Article

Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics

Authors: Simon Van Herck1, Bruno G. De Geest1
1 Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
Correspondence to: Bruno G. De Geest: br.degeest@ugent.be,
DOI: 10.103810.1038/s41401-020-0425-3
Received: 9 January 2020
Accepted: 20 April 2020
Advance online: 25 May 2020

Abstract

The advent of immunotherapy is a game changer in cancer therapy with monoclonal antibody- and T cell-based therapeutics being the current flagships. Small molecule immunotherapeutics might offer advantages over the biological drugs in terms of complexity, tissue penetration, manufacturing cost, stability, and shelf life. However, small molecule drugs are prone to rapid systemic distribution, which might induce severe off-target side effects. Nanotechnology could aid in the formulation of the drug molecules to improve their delivery to specific immune cell subsets. In this review we summarize the current efforts in changing the pharmacokinetic profile of small molecule immunotherapeutics with a strong focus on Toll-like receptor agonists. In addition, we give our vision on limitations and future pathways in the route of nanomedicine to the clinical practice.
Keywords: cancer immunotherapy; small molecule drugs; pharmacokinetic profile; nanomedicine; toll-like receptors; stimulator of interferon genes (STING)

Article Options

Download Citation

Cited times in Scopus